New eye implant could drastically reduce injections for diabetic vision loss
NCT ID NCT07449936
Summary
This study is testing a new, long-acting eye implant called EYP-1901 against the standard aflibercept injections for diabetic macular edema (DME), a common cause of vision loss in people with diabetes. The main goal is to see if the implant can control the disease just as well while requiring far fewer injections over a year. It will involve about 240 people who have DME and are either new to treatment or have had prior injections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Global Research Management, Inc.
RECRUITINGGlendale, California, 91204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Midwest Eye Institute - Carmel
RECRUITINGCarmel, Indiana, 11220, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mt. Olympus Medical Research
RECRUITINGHouston, Texas, 77479, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.